Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
37
JSPR Quote, Financials, Valuation and Earnings
Last price:
$1.65
Seasonality move
:
45.02%
Day range:
$1.51 - $1.58
52-week range:
$1.39 - $7.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.70x
Volume:
258.2K
Avg. volume:
902.7K
1-year change:
-73.16%
Market cap:
$42.8M
Revenue:
--
EPS (TTM):
-$5.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JSPR
Jasper Therapeutics, Inc.
|
-- | -$0.87 | -- | -51.67% | $9.80 |
|
CYTK
Cytokinetics, Inc.
|
$8M | -$1.37 | 857.99% | -14.11% | $89.44 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JSPR
Jasper Therapeutics, Inc.
|
$1.53 | $9.80 | $42.8M | -- | $0.00 | 0% | -- |
|
CYTK
Cytokinetics, Inc.
|
$63.19 | $89.44 | $7.7B | -- | $0.00 | 0% | 86.23x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.15 | $0.85 | $397.4M | 5.29x | $0.80 | 0% | 6.12x |
|
OGEN
Oragenics, Inc.
|
$0.81 | $2.00 | $662.7K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JSPR
Jasper Therapeutics, Inc.
|
12.83% | -0.056 | 2.56% | 2.42x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.240 | 17.83% | 6.81x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JSPR
Jasper Therapeutics, Inc.
|
-$229K | -$19.2M | -195.32% | -204.39% | -- | -$17M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Jasper Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns JSPR or CYTK?
Cytokinetics, Inc. has a net margin of -- compared to Jasper Therapeutics, Inc.'s net margin of -15814.98%. Jasper Therapeutics, Inc.'s return on equity of -204.39% beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JSPRJasper Therapeutics, Inc.-- -$1.13 $13.3M CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About JSPR or CYTK?
Jasper Therapeutics, Inc. has a consensus price target of $9.80, signalling upside risk potential of 540.52%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $89.44 which suggests that it could grow by 41.55%. Given that Jasper Therapeutics, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Jasper Therapeutics, Inc. is more attractive than Cytokinetics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JSPRJasper Therapeutics, Inc.3 2 0 CYTKCytokinetics, Inc.10 3 0 -
Is JSPR or CYTK More Risky?
Jasper Therapeutics, Inc. has a beta of 2.688, which suggesting that the stock is 168.779% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.718%.
-
Which is a Better Dividend Stock JSPR or CYTK?
Jasper Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jasper Therapeutics, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JSPR or CYTK?
Jasper Therapeutics, Inc. quarterly revenues are --, which are smaller than Cytokinetics, Inc. quarterly revenues of $1.9M. Jasper Therapeutics, Inc.'s net income of -$18.7M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Jasper Therapeutics, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jasper Therapeutics, Inc. is -- versus 86.23x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JSPRJasper Therapeutics, Inc.-- -- -- -$18.7M CYTKCytokinetics, Inc.86.23x -- $1.9M -$306.2M
-
Which has Higher Returns JSPR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Jasper Therapeutics, Inc.'s net margin of -255.85%. Jasper Therapeutics, Inc.'s return on equity of -204.39% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital JSPRJasper Therapeutics, Inc.-- -$1.13 $13.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About JSPR or NBY?
Jasper Therapeutics, Inc. has a consensus price target of $9.80, signalling upside risk potential of 540.52%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.02%. Given that Jasper Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Jasper Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JSPRJasper Therapeutics, Inc.3 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is JSPR or NBY More Risky?
Jasper Therapeutics, Inc. has a beta of 2.688, which suggesting that the stock is 168.779% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock JSPR or NBY?
Jasper Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Jasper Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JSPR or NBY?
Jasper Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Jasper Therapeutics, Inc.'s net income of -$18.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Jasper Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jasper Therapeutics, Inc. is -- versus 6.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JSPRJasper Therapeutics, Inc.-- -- -- -$18.7M NBYNovaBay Pharmaceuticals, Inc.6.12x 5.29x $521K -$1.3M
-
Which has Higher Returns JSPR or OGEN?
Oragenics, Inc. has a net margin of -- compared to Jasper Therapeutics, Inc.'s net margin of --. Jasper Therapeutics, Inc.'s return on equity of -204.39% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital JSPRJasper Therapeutics, Inc.-- -$1.13 $13.3M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About JSPR or OGEN?
Jasper Therapeutics, Inc. has a consensus price target of $9.80, signalling upside risk potential of 540.52%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 148.36%. Given that Jasper Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Jasper Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JSPRJasper Therapeutics, Inc.3 2 0 OGENOragenics, Inc.1 0 0 -
Is JSPR or OGEN More Risky?
Jasper Therapeutics, Inc. has a beta of 2.688, which suggesting that the stock is 168.779% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock JSPR or OGEN?
Jasper Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jasper Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JSPR or OGEN?
Jasper Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Jasper Therapeutics, Inc.'s net income of -$18.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Jasper Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jasper Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JSPRJasper Therapeutics, Inc.-- -- -- -$18.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns JSPR or PTN?
Palatin Technologies has a net margin of -- compared to Jasper Therapeutics, Inc.'s net margin of --. Jasper Therapeutics, Inc.'s return on equity of -204.39% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JSPRJasper Therapeutics, Inc.-- -$1.13 $13.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About JSPR or PTN?
Jasper Therapeutics, Inc. has a consensus price target of $9.80, signalling upside risk potential of 540.52%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Jasper Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Jasper Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JSPRJasper Therapeutics, Inc.3 2 0 PTNPalatin Technologies0 0 0 -
Is JSPR or PTN More Risky?
Jasper Therapeutics, Inc. has a beta of 2.688, which suggesting that the stock is 168.779% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock JSPR or PTN?
Jasper Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jasper Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JSPR or PTN?
Jasper Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Jasper Therapeutics, Inc.'s net income of -$18.7M is higher than Palatin Technologies's net income of --. Notably, Jasper Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jasper Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JSPRJasper Therapeutics, Inc.-- -- -- -$18.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns JSPR or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Jasper Therapeutics, Inc.'s net margin of --. Jasper Therapeutics, Inc.'s return on equity of -204.39% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital JSPRJasper Therapeutics, Inc.-- -$1.13 $13.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About JSPR or TOVX?
Jasper Therapeutics, Inc. has a consensus price target of $9.80, signalling upside risk potential of 540.52%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3386.06%. Given that Theriva Biologics, Inc. has higher upside potential than Jasper Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Jasper Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JSPRJasper Therapeutics, Inc.3 2 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is JSPR or TOVX More Risky?
Jasper Therapeutics, Inc. has a beta of 2.688, which suggesting that the stock is 168.779% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock JSPR or TOVX?
Jasper Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jasper Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JSPR or TOVX?
Jasper Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Jasper Therapeutics, Inc.'s net income of -$18.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Jasper Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jasper Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JSPRJasper Therapeutics, Inc.-- -- -- -$18.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
52
CVLT alert for Jan 27
Commvault Systems, Inc. [CVLT] is down 31.39% over the past day.
Sell
47
AGYS alert for Jan 27
Agilysys, Inc. [AGYS] is down 20.55% over the past day.
Buy
71
GLSI alert for Jan 27
Greenwich LifeSciences, Inc. [GLSI] is up 7.81% over the past day.
